Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 03 2020
Historique:
pubmed: 13 11 2019
medline: 9 2 2021
entrez: 13 11 2019
Statut: ppublish

Résumé

Toxoplasma infection remains as the most common cause of focal brain lesions among people living with HIV (PLHIV) despite the decline in opportunistic infections with the introduction of antiretroviral treatment. This study was conducted to provide a summary of evidence about the seroprevalence of Toxoplasma gondii and prevalence of active T. gondii infection and associated risk factors among PLHIV. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Scopus, PubMed, Science Direct and EMBASE were searched from 1997 to July 2018. All peer-reviewed original research articles describing T. gondii infection among PLHIV with different diagnostic methods were included. Incoherence and heterogeneity between studies were quantified by I index and Cochran's Q test. Publication and population bias were assessed with funnel plots and Egger's regression asymmetry test. All statistical analyses were performed using StatsDirect. In total, 111 studies from 37 countries assessing 66 139 blood samples were included in this study. The pooled prevalence of T. gondii infection among PLHIV was 3.24% by IgM and 26.22% by molecular methods using the random-effects model. Pooled seroprevalence of T. gondii by IgG was 44.22%. There was a relationship between Toxoplasma prevalence and sex, raw meat consumption, contact with cat and knowledge about toxoplasmosis. High Toxoplasma seroprevalence among PLHIV observed in this study emphasizes the need for implementing screening and prophylaxis tailored to the local context. Owing to the serious and significant clinical manifestations of the parasite in case of reactivation, early identification of seropositivity for initiating prophylaxis among those with a CD4 cell count of less than 200 cells/ml is recommended.

Identifiants

pubmed: 31714356
doi: 10.1097/QAD.0000000000002424
pii: 00002030-202003010-00014
doi:

Substances chimiques

Antibodies, Protozoan 0

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

469-474

Références

Robert-Gangneux F, Dardé M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 2012; 25:264–296.
Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, et al. Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta Trop 2014; 137:185–194.
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis 2012; 44:805–814.
Flegr J, Preiss M, Klose J. Toxoplasmosis-associated difference in intelligence and personality in men depends on their rhesus blood group but not ABO blood group. PLoS One 2013; 8:e61272.
Foroutan-Rad M, Majidiani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in blood donors: a systematic review and meta-analysis. Transfus Med Rev 2016; 30:116–122.
Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Fut Microbiol 2009; 4:1363–1379.
Ahmadpour E, Daryani A, Sharif M, Sarvi S, Aarabi M, Mizani A, et al. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries 2014; 8:1503–1510.
Basavaraju A. Toxoplasmosis in HIV infection: an overview. Trop Parasitol 2016; 6:129.
Nissapatorn V, Lee C, Quek KF, Leong CL, Mahmud R, Abdullah KA. Toxoplasmosis in HIV/AIDS patients: a current situation. Jpn J Infect Dis 2004; 57:160–165.
Nissapatorn V. Toxoplasma gondii and HIV: a never-ending story. Lancet HIV 2017; 4:e146–e147.
Wang Z-D, Wang S-C, Liu H-H, Ma H-Y, Li Z-Y, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis. Lancet HIV 2017; 4:e177–e188.
Addebbous A, Adarmouch L, Tali A, Laboudi M, Amine M, Aajly L, et al. IgG anti-Toxoplasma antibodies among asymptomatic HIV-infected patients in Marrakesh-Morocco. Acta Trop 2012; 123:49–52.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4:1.
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 2015; 13:147–153.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188.
Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R. 2018; New York, NY: Springer, 28–36.
IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016; 6:e010247.
Ninmongo L, McBride W, Millan J, Wilson K. Seroprevalence of anti-Toxoplasma gondii antibodies in HIV/AIDS patients and healthy blood donors at the Port Moresby General Hospital, Papua New Guinea. P N G Med J 2012; 55:88.
Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol 2019; 4:1363–1379.
Denkers EY. T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microb Infect 1999; 1:699–708.
Wilson DC, Grotenbreg GM, Liu K, Zhao Y, Frickel E-M, Gubbels M-J, et al. Differential regulation of effector-and central-memory responses to Toxoplasma gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells. PLoS Pathog 2010; 6:e1000815.
Meira CS, Costa-Silva TA, Vidal JE, Ferreira IM, Hiramoto RM, Pereira-Chioccola VL. Use of the serum reactivity against Toxoplasma gondii excreted–secreted antigens in cerebral toxoplasmosis diagnosis in human immunodeficiency virus-infected patients. J Med Microbiol 2008; 57:845–850.
Chardes T, Bourguin I, Mevelec M, Dubremetz J, Bout D. Antibody responses to Toxoplasma gondii in sera, intestinal secretions, and milk from orally infected mice and characterization of target antigens. Infect Immun 1990; 58:1240–1246.
Derouin F, Leport C, Pueyo S, Morlat P, Letrillart B, Chene G, et al. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. AIDS 1996; 10:1521–1527.
Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009; 39:1385–1394.
Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am J Trop Med Hyg 2007; 77:405–410.
Hegab SM, Al-Mutawa SA. Immunopathogenesis of toxoplasmosis. Clin Exp Med 2003; 3:84–105.
Ogoina D, Onyemelukwe GC, Musa BO, Obiako RO. Seroprevalence of IgM and IgG antibodies to Toxoplasma infection in healthy and HIV-positive adults from Northern Nigeria. J Infect Dev Ctries 2013; 7:398–403.
Mesquita RT, Vidal JE, Pereira-Chioccola VL. Molecular diagnosis of cerebral toxoplasmosis: comparing markers that determine Toxoplasma gondii by PCR in peripheral blood from HIV-infected patients. Braz J Infect Dis 2010; 14:346–350.
Brenier-Pinchart M, Morand-Bui V, Fricker-Hidalgo H, Equy V, Marlu R, Pelloux H. Adapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal control. Parasite 2007; 14:149–154.
Schoondermark-Van de Ven E, Galama J, Kraaijeveld C, Van Druten J, Meuwissen J, Melchers W. Value of the polymerase chain reaction for the detection of Toxoplasma gondii in cerebrospinal fluid from patients with AIDS. Clin Infect Dis 1993; 16:661–666.
Deeks J, Higgins J, Altman D, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 (updated March 2011). The Cochrane Collaboration. Chichester: John Wiley & Sons Ltd; 2011.

Auteurs

Hanie Safarpour (H)

Infectious and Tropical Diseases Research Center.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Muge Cevik (M)

Division of Infection and Global Health Research, School of Medicine, University of St Andrews, Fife, UK.

Mehdi Zarean (M)

Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Aleksandra Barac (A)

Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia.

Kareem Hatam-Nahavandi (K)

Iranshahr University of Medical Sciences, Iranshahr.

Mohammad T Rahimi (MT)

School of Medicine, Shahroud University of Medical Sciences, Shahroud.

Hossein Bannazadeh Baghi (H)

Immunology Research Center.

Tohid J Koshki (TJ)

Department of Statistics and Epidemiology, Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz.

Abdol S Pagheh (AS)

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand.

Firooz Shahrivar (F)

Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran.

Mina Ebrahimi (M)

Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran.

Ehsan Ahmadpour (E)

Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH